Introduction:
Metabolic Syndrome (MetS) is an endocrinopathy that starts with insulin
resistance, accompanied by a range of systemic disorders such as glucose
intolerance, diabetes mellitus (DM), abdominal obesity, dyslipidemia,
hypertension (HT), and coronary artery disease (CAD) [1]. MetS is
one of the most important health problems with increasing prevalence and
awareness. Due to the increased prevalence of MetS in society, the
number of studies on this subject has increased. The prevalence of MetS,
which is considered to be an important health problem in developed and
developing countries, varies depending on age and gender [2, 3].
Although MetS was previously thought to cause only cardiovascular
problems, new data reveal that it occurs with some urological disorders.
The prevalence of erectile dysfunction, infertility, stone disease,
overactive bladder, benign prostatic hyperplasia has also increased in
these patients. At the same time, its relationship with malignancy by
causing angiogenesis and oxidative stress due to baseline insulin
resistance has been revealed. It has been observed to increase the
incidence and progression of cancers. MetS has also caused an increase
in the incidence of prostate cancer and Renal Cell Carcinoma (RCC)
[4-7].
RCC accounts for 2-3% of all adult malignant masses and for 85-90% of
malignant tumors of the kidney. RCC is the highest mortality rate among
the urological malignancies. Although RCC ranks third after prostate and
bladder cancer among urological cancers, it accounts for 40% of deaths
due to urinary system cancers. Knowledge of the etiology of RCC plays an
important role in understanding the onset of histological cancer and its
progression to invasive cancer [8, 9]. Although there is no definite
data that MetS components are effective in the development of RCC, some
studies have reported that especially high-calorie dietary habits and
obesity have some roles in the development of RCC and some studies have
reported that DM, HT, and hypertriglyceridemia are important in the
development of RCC [10-13].
This study aimed to reveal which MetS components have more clinical
significance to compare kidney tumor characteristics of patients with
and without MetS and to determine clinically significant risk factors
for patient groups.